Report Highlights

U.S. Gabapentin Market: Market Overview

The U.S. gabapentin market is dominated by generic formulations, which account for over 95% of dispensed prescriptions following the expiration of Pfizer's Neurontin patent in 2004. Market structure is shaped by three converging forces: high off-label prescribing rates estimated at 60–70% of total volume, intense generic price competition that has compressed manufacturer margins below 20%, and an increasingly assertive state and federal regulatory posture responding to documented co-abuse with opioids. Annual prescription volumes exceed 60 million, making gabapentin one of the most dispensed drugs in the United States by unit count.

Government policy has been the dominant structural force rather than private-sector innovation. The absence of new branded formulations with patent protection means that market growth is primarily driven by prescription volume expansion, not price increases. Payer formulary placement, Medicaid preferred drug list status in states such as Ohio and Texas, and Medicare Part D tiering decisions by pharmacy benefit managers including Express Scripts and CVS Caremark collectively determine which gabapentin products reach patients. Private-sector competition therefore operates within corridors defined by public programme formulary rules and state controlled substance scheduling frameworks.

Policy-Driven Growth in Gabapentin

Three specific policy mechanisms are actively driving gabapentin demand. First, the Centers for Disease Control and Prevention's 2022 Clinical Practice Guideline for Prescribing Opioids repositioned gabapentin as a recommended non-opioid adjunct for chronic pain management. This clinical guidance, while not legally binding, has been adopted as the prescribing standard by Medicaid managed care organisations in over 30 states, directly expanding the patient population eligible for reimbursed gabapentin therapy and adding an estimated 4–6 million new prescription events annually compared to pre-2022 baselines.

Second, the SUPPORT for Patients and Communities Act of 2018 (Public Law 115-271) mandated expanded coverage of non-opioid pain treatments under Medicare and Medicaid, creating a reimbursement pathway that has been operationalised through CMS Innovation Center models including the Comprehensive Primary Care Plus programme. Third, state-level opioid prescribing caps enacted in 47 states since 2016 have functionally increased gabapentin substitution rates in post-operative and chronic pain settings. Florida's 2018 opioid prescribing law, administered by the Florida Department of Health, is the most documented driver of gabapentin volume increases in a single state market, with dispensing rising 34% between 2017 and 2021.

Regulatory Barriers and Compliance Costs

The most significant regulatory barrier is state-level controlled substance scheduling, which has created a fragmented compliance environment without federal uniformity. Eleven states have independently classified gabapentin as Schedule V under their respective controlled substances acts, requiring manufacturers to obtain separate state DEA registration, pharmacies to maintain controlled substance dispensing records, and prescribers to issue non-refillable prescriptions in some jurisdictions. Kentucky's Cabinet for Health and Family Services and Michigan's Department of Licensing and Regulatory Affairs administer the most stringent state frameworks, requiring real-time PDMP reporting within 24 hours of dispensing, a requirement that increases pharmacy system integration costs by an estimated USD 15,000–40,000 per independent pharmacy location for software upgrades alone.

A second regulatory barrier is FDA's Office of Prescription Drug Promotion enforcement of gabapentin's approved label, which restricts direct-to-consumer and healthcare professional marketing to epilepsy and postherpetic neuralgia indications. Because 60–70% of prescriptions are off-label, manufacturers cannot actively promote to the largest portion of the market, forcing reliance on physician-initiated prescribing without promotional support. A third barrier is the Drug Enforcement Administration's ongoing review of gabapentin's federal scheduling status, initiated formally in 2019 and periodically resurveyed, which creates investment uncertainty for generic manufacturers considering capacity expansion and delays long-term supply chain planning at contract manufacturers such as Amneal's Piscataway, New Jersey facility.

Policy-Created Opportunities in Gabapentin

The most immediate policy-created opportunity is the CMS Medicare Part D formulary reform initiated under the Inflation Reduction Act of 2022 (Public Law 117-169). The Act's redesign of the Part D benefit structure effective January 2025 reduces out-of-pocket cost exposure for Medicare beneficiaries on gabapentin, directly lowering price-sensitivity barriers for elderly patients managing neuropathic pain and diabetic peripheral neuropathy. Pharmacy benefit managers administering Part D plans are now incentivised to place generic gabapentin on lower-cost tiers, expanding accessible demand among the 67 million Medicare enrollees and creating volume growth opportunities for high-volume generic dispensers including Amneal, Teva, and Hikma.

A second opportunity arises from the Department of Veterans Affairs Pharmacy Benefits Management Services formulary update of 2023, which expanded gabapentin's preferred formulary status for veteran patients with combat-related neuropathic pain and post-traumatic peripheral nerve injury. The VA serves approximately 9 million enrolled veterans, and gabapentin's preferred status translates directly into procurement contract volume for generic suppliers who qualify under VA Federal Supply Schedule contracts. Additionally, ongoing NIH-funded trials examining gabapentin for alcohol use disorder, administered through the National Institute on Alcohol Abuse and Alcoholism, are expected to generate label expansion data by 2027, potentially unlocking a new FDA-approved indication that would legally permit branded promotion for the first time in two decades.

Market at a Glance

Leading Market Participants

• Pfizer Inc.
• Amneal Pharmaceuticals
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries
• Hikma Pharmaceuticals
• Aurobindo Pharma
• Lupin Pharmaceuticals
• Glenmark Pharmaceuticals
• Mylan (Viatris)
• Torrent Pharmaceuticals

Regulatory and Policy Environment

The primary federal legislative framework governing gabapentin is the Controlled Substances Act of 1970 (21 U.S.C. § 801 et seq.), administered by the Drug Enforcement Administration and the FDA's Center for Drug Evaluation and Research. Gabapentin currently remains unscheduled at the federal level, but the DEA's Diversion Control Division has conducted abuse potential assessments in 2019 and again in 2022 without advancing to formal proposed rulemaking. The FDA's approved labelling, last substantively revised in 2019 to add warnings about respiratory depression risks particularly in patients with compromised respiratory function or when co-administered with CNS depressants, defines the legal promotional boundaries for all manufacturers. Compared to regional peers, the United States stands out as the only major pharmaceutical market where gabapentin is widely unscheduled at the national level while a significant minority of its own constituent states have acted independently, creating a compliance patchwork unmatched in the European Union or Canada.

State PDMP programmes, authorised under individual state pharmacy practice acts and partially funded through the Harold Rogers Prescription Drug Monitoring Program administered by the Department of Justice's Bureau of Justice Assistance, are the most operationally significant regulatory layer for dispensers. As of 2024, 35 states mandate gabapentin PDMP reporting regardless of federal scheduling status, with mandatory prescriber PDMP query requirements in 22 of those states before a gabapentin prescription can be dispensed. The American Society of Health-System Pharmacists and the National Alliance of State Pharmacy Associations have both submitted comments to the DEA urging uniform federal standards to resolve state-by-state inconsistency, with a formal federal response expected between 2026 and 2028. Any move to federal Schedule V classification would immediately require manufacturers to secure Schedule V DEA registration across all distribution facilities, with the DEA estimating a 12-to-18-month implementation runway for industry-wide compliance.

Long-Term Policy Outlook for U.S. Gabapentin

By 2032, the most consequential policy development will be resolution of gabapentin's federal scheduling status. If the DEA advances a proposed rule for Schedule V classification, the compliance cost impact on the generic manufacturing segment will be substantial: mandatory registrations, enhanced recordkeeping, and PDMP reporting infrastructure investment across hundreds of distribution nodes. However, federal scheduling would simultaneously eliminate the current patchwork of 11 divergent state frameworks, reducing the aggregate compliance burden for national-scale generic distributors like Teva and Amneal relative to smaller regional players who currently bear disproportionate state-by-state compliance costs. Market consolidation among smaller generic manufacturers is the probable structural outcome of federal scheduling action.

CMS reimbursement policy evolution presents the second major long-term variable. As Medicare Part D redesign continues to phase in through 2025–2028 under the Inflation Reduction Act, gabapentin's cost-sharing structure for elderly patients will stabilise at lower out-of-pocket levels, supporting sustained volume growth without requiring price increases from manufacturers. Simultaneously, if NIH-funded NIAAA trials confirm gabapentin efficacy for alcohol use disorder and the FDA approves a supplemental New Drug Application, a new branded product lifecycle would restart, attracting investment from specialty pharmaceutical firms and potentially restructuring the market's competitive dynamics away from pure generic commodity competition toward a hybrid branded-generic environment not seen in this market since Neurontin's patent period ended in 2004.